Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827968 | 0.82 | HTR2A (0.80) | HTR2AALDH1A1HTTRAB9A | |
| SCHEMBL12524469 | 0.81 | HTR2A (0.74) | HTR2AMAPTALDH1A1HTTRAB9A | |
| SCHEMBL14621621 | 0.79 | HTR2A (0.74) | HTR2AALDH1A1HTTRAB9A | |
| SCHEMBL6395093 | 0.78 | HTR2A (0.62) | HTR2AMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5215283 | 0.78 | CYP3A4 (0.60) | MEN1KMT2ASMN1; SMN2CYP3A4MAPT | |
| SCHEMBL29586964 | 0.78 | HTR2A (0.62) | HTR2AMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13553426 | 0.78 | KCNJ1 (0.55) | HTR2ASMN1; SMN2MAPTALDH1A1POLB | |
| SCHEMBL14538159 | 0.78 | HTR2A (0.59) | HTR2AALDH1A1HTTRAB9A | |
| SCHEMBL669310 | 0.77 | CYP3A4 (0.67) | MEN1KMT2ASMN1; SMN2CYP3A4MAPT | |
| SCHEMBL25187205 | 0.76 | HTR2A (0.70) | HTR2AMEN1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235008-B1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-16 | — | — | EP | disclosed |
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC BVBA | 2010-12-02 | — | — | US | disclosed |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC BVBA | 2010-12-02 | — | — | US | disclosed |
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC BVBA | 2010-12-02 | — | — | US | disclosed |
| EP-2235008-A2 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | Tibotec Pharmaceuticals (IE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009071650-A2 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071650-A2 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305073-A1 | AMIDE COMPOUNDS AS BOOSTERS OF ANTIVIRALS | CYP3A5, CYP3A4, CYP3A43 | HTR2A 1950/4885MEN1 4833/4885KMT2A 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.